Whereas inhibition of PKC using pharmacological inhibitors or aprinocarsen, a PKCα antisense oligonucleotide, failed in clinical trials for cancer, these same molecules may be more effective if repurposed for AD [36]. Here, PRKCA is linked to cancer.